Vaccitech PLC
F:2AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Australian Vintage Ltd
ASX:AVG
|
AU |
|
Flexsteel Industries Inc
NASDAQ:FLXS
|
US |
|
Nagaileben Co Ltd
TSE:7447
|
JP |
|
EFORT Intelligent Equipment Co Ltd
SSE:688165
|
CN |
|
Federal Realty Investment Trust
NYSE:FRT
|
US |
|
Robinsons Retail Holdings Inc
OTC:RRETY
|
PH |
|
Trigg Mining Ltd
ASX:TMG
|
AU |
|
Computer Management Co Ltd
TSE:4491
|
JP |
|
PiPEDO HD Inc
TSE:3919
|
JP |
|
Y
|
YIT Oyj
OMXH:YIT
|
FI |
|
Moneyme Ltd
ASX:MME
|
AU |
|
C
|
Ching Lee Holdings Ltd
HKEX:3728
|
HK |
|
Bellway PLC
LSE:BWY
|
UK |
|
Medigus Ltd
NASDAQ:XYLO
|
IL |
|
A
|
Ackerstein Group Ltd
TASE:ACKR
|
IL |
|
Y
|
Yatsen Holding Ltd
NYSE:YSG
|
CN |
Vaccitech PLC
Total Equity
Vaccitech PLC
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vaccitech PLC
F:2AB
|
Total Equity
$74.2m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Total Equity
$401.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Equity
£381m
|
CAGR 3-Years
11%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Total Equity
$154.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
79%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Equity
£504m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Total Equity
£32.7m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
7%
|
|
Vaccitech PLC
Glance View
Vaccitech Plc operates as a holding company. The company is headquartered in Oxford, Oxfordshire and currently employs 72 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The firm uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The firm has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).
See Also
What is Vaccitech PLC's Total Equity?
Total Equity
74.2m
USD
Based on the financial report for Dec 31, 2025, Vaccitech PLC's Total Equity amounts to 74.2m USD.
What is Vaccitech PLC's Total Equity growth rate?
Total Equity CAGR 3Y
-33%
Over the last year, the Total Equity growth was -43%. The average annual Total Equity growth rates for Vaccitech PLC have been -33% over the past three years .
